KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silicon Laboratories (SLAB) Other Accumulated Expenses (2016 - 2026)

Silicon Laboratories has reported Other Accumulated Expenses over the past 15 years, most recently at $87.7 million for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses rose 67.51% year-over-year to $87.7 million; the TTM value through Jan 2026 reached $87.7 million, up 67.51%, while the annual FY2026 figure was $87.7 million, 67.51% up from the prior year.
  • Other Accumulated Expenses for Q1 2026 was $87.7 million at Silicon Laboratories, up from $81.2 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $160.2 million in Q2 2022 and troughed at $33.9 million in Q4 2022.
  • A 5-year average of $81.7 million and a median of $65.2 million in 2024 define the central range for Other Accumulated Expenses.
  • On a YoY basis, Other Accumulated Expenses climbed as much as 437.48% in 2022 and fell as far as 78.4% in 2022.
  • Year by year, Other Accumulated Expenses stood at $33.9 million in 2022, then skyrocketed by 73.77% to $59.0 million in 2023, then decreased by 11.18% to $52.4 million in 2024, then surged by 55.1% to $81.2 million in 2025, then grew by 8.0% to $87.7 million in 2026.
  • Business Quant data shows Other Accumulated Expenses for SLAB at $87.7 million in Q1 2026, $81.2 million in Q4 2025, and $58.7 million in Q3 2025.